Home » Business » Manufacturing
German drug firm invests to tap growing market
By Ding Yining |
00:59 UTC+8 October 22, 2009
|
Print Edition
Print Edition
GERMANY-BASED Boehringer Ingelheim yesterday said it will invest 100 million euros (US$149 million) on Chinese mainland to tap the pharmaceutical market.
The drug maker will expand its pharmaceutical production capacity at its plant in Shanghai's Zhangjiang High-Tech Park and set up a Chemical Competency Center.
The center will focus on developing new vaccines for viruses that are peculiar in Asia Pacific. The drug maker's investment also includes a new animal health products manufacturing facility.
"We're hoping to see a 35 percent annual sales growth in China in the next five years," said David Preston, chairman and CEO of Boehringer Ingelheim Shanghai Pharmaceutical Co. "We are relatively a late comer in the market so we have to catch up in the next few years."
The firm will also recruit an extra 500 sales personnel in China by as early as December, bringing its total employees in the country to around 1,500.
"Expanding our business in emerging markets will be our key strategy and the driving thrust for our future growth," said Engelbert C. Tjeenk Willink, member of the board of BI.
It aims to raise its market share in China to 1.48 percent by 2020 from 0.4 percent now, said IMS, a pharmaceutical consultancy.
The drug maker will expand its pharmaceutical production capacity at its plant in Shanghai's Zhangjiang High-Tech Park and set up a Chemical Competency Center.
The center will focus on developing new vaccines for viruses that are peculiar in Asia Pacific. The drug maker's investment also includes a new animal health products manufacturing facility.
"We're hoping to see a 35 percent annual sales growth in China in the next five years," said David Preston, chairman and CEO of Boehringer Ingelheim Shanghai Pharmaceutical Co. "We are relatively a late comer in the market so we have to catch up in the next few years."
The firm will also recruit an extra 500 sales personnel in China by as early as December, bringing its total employees in the country to around 1,500.
"Expanding our business in emerging markets will be our key strategy and the driving thrust for our future growth," said Engelbert C. Tjeenk Willink, member of the board of BI.
It aims to raise its market share in China to 1.48 percent by 2020 from 0.4 percent now, said IMS, a pharmaceutical consultancy.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 沪ICP证：沪ICP备05050403号-1
- |
- 互联网新闻信息服务许可证：31120180004
- |
- 网络视听许可证：0909346
- |
- 广播电视节目制作许可证：沪字第354号
- |
- 增值电信业务经营许可证：沪B2-20120012
Copyright © 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
